Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03338803 · ClinicalTrials.gov registry record
Real World Glycemic Effectiveness of Linagliptin
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 11,001
- Enrollment target
NCT03338803 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 11,001 participants.
The verdict
NCT03338803 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 11,001 participants
- Enrollment target
Study Summary
A non-interventional cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data from providers across the United States to determine whether there is comparable effectiveness of linagliptin on glycemic effectiveness
Interventions
- DRUG Linagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,001 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2018-02-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03338803
The ClinicalTrials.gov registry entry for NCT03338803 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11,001 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Linagliptin is the first listed.
NCT03338803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03338803 about?
NCT03338803 is a clinical study titled "Real World Glycemic Effectiveness of Linagliptin". A non-interventional cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data from providers across the United States to determine whether there is comparable effectiveness of linagliptin on glycemic effectiveness
What is the current status of trial NCT03338803?
This trial is currently completed. The enrollment target is 11,001 participants. The study started on 2017-11-21. Estimated completion is 2018-02-02.
What interventions are being tested in trial NCT03338803?
The interventions under investigation include: Linagliptin (DRUG).
Who is sponsoring clinical trial NCT03338803?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.